Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ClinicalTrials.gov 24,857 recruiting now free trial finder

Find a clinical trial that's recruiting now

Search 24,857 actively recruiting US clinical trials by condition, drug, or state, each entry links straight to its NIH ClinicalTrials.gov record so you can check eligibility and contact the study team.

24,857
trials recruiting now
14%
of all US trials open to enrollment
52
states with recruiting sites

A trial is listed as recruiting when its sponsor has marked it open to new participants on the public registry. Type a condition or drug name (for example, "breast cancer" or "pembrolizumab") to narrow the list, and add a state to find studies with a site near you. Results are ordered with the most relevant recruiting studies first; each card shows the study phase and enrollment target, and opens the full record, including eligibility criteria and contact details, on ClinicalTrials.gov.

100 trials found

Recruiting 200,000 target

Connect for Cancer Prevention Study (Connect)

National Cancer Institute (NCI)

NCT04609072

Recruiting 40,000 target

Stroke Thrombectomy and Aneurysm Registry

Medical University of South Carolina

NCT04994756

Recruiting 25,000 target

Parkinson's Foundation PD GENEration Genetic Registry

Parkinson's Foundation

NCT04994015

Recruiting NA 24,000 target

The Vanguard Study: Testing a New Way to Screen for Cancer

National Cancer Institute (NCI)

NCT06995898

Recruiting 10,000 target

Umbrella Study for Analysis of Data Related to Patients With Cancer

Tempus AI

NCT06018753

Recruiting Phase 4 7,410 target

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

VA Office of Research and Development

NCT02915198

Recruiting 5,000 target

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Duke University

NCT04278404

Recruiting NA 2,996 target

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Stanford University

NCT05297734

Recruiting NA 2,500 target

Study of Student Flourishing

Flourish Science

NCT07259746

Recruiting Phase 3 2,000 target

Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction

Uppsala University

NCT02901184

Recruiting Phase 3 1,980 target

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Eli Lilly and Company

NCT07321886

Recruiting NA 1,780 target

'Ai Pono Cooking Demonstrations

University of Hawaii

NCT06526650

Recruiting 1,600 target

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Bristol-Myers Squibb

NCT05489705

Recruiting 1,400 target

EXoPERT EMERALD Clinical Study

EXoPERT

NCT07186296

Recruiting Phase 3 1,280 target

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

Novo Nordisk A/S

NCT07207811

Recruiting Phase 3 1,275 target

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Novartis Pharmaceuticals

NCT07225504

Recruiting Phase 2 1,217 target

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Eli Lilly and Company

NCT06143956

Recruiting 1,200 target

GEMINI-NSCLC: NSCLC Biomarker Study

Tempus AI

NCT05236114

Recruiting NA 1,094 target

Brain Oxygen Optimization in Severe TBI, Phase 3

University of Michigan

NCT03754114

Recruiting 1,000 target

Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

M.D. Anderson Cancer Center

NCT04739072

Recruiting Phase 3 990 target

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

Merz Therapeutics

NCT07018700

Recruiting Phase 2 982 target

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Pfizer

NCT06989437

Recruiting Phase 3 974 target

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

Eli Lilly and Company

NCT06948422

Recruiting 950 target

An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample

U.S. Army Medical Research and Development Command

NCT04180930

Recruiting Phase 3 900 target

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Hoffmann-La Roche

NCT07174310

Recruiting Phase 2 800 target

Department of Defense PTSD Adaptive Platform Trial - Master Protocol

Global Coalition for Adaptive Research

NCT05422612

Recruiting Phase 3 800 target

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Hoffmann-La Roche

NCT07169578

Recruiting Phase 1 796 target

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

DualityBio

NCT05150691

Recruiting Phase 3 780 target

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

Merz Therapeutics

NCT07018713

Recruiting Phase 3 777 target

Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy

SWOG Cancer Research Network

NCT05642611

Recruiting Phase 2 770 target

A Study to Learn About mRNA Vaccines Against Influenza in Adults

Pfizer

NCT07431853

Recruiting Phase 3 700 target

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

AstraZeneca

NCT07044336

Recruiting Phase 3 700 target

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Incyte Corporation

NCT07284849

Recruiting Phase 3 698 target

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

AbbVie

NCT04928846

Recruiting Phase 3 668 target

Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial

University of Rochester

NCT05006482

Recruiting Phase 3 659 target

Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.

Granata Bio Corporation

NCT07216742

Recruiting NA 656 target

Contraceptive Efficacy Study of Ovaprene

Daré Bioscience

NCT06127199

Recruiting Phase 3 625 target

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

AstraZeneca

NCT06103864

Recruiting NA 600 target

Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment

NRG Oncology

NCT06279013

Recruiting Phase 3 600 target

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Eli Lilly and Company

NCT07357415

Recruiting 600 target

Lesion Composition and Quantitative Imaging Analysis on Breast Cancer Diagnosis

University of Hawaii

NCT05369546

Recruiting Phase 3 600 target

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

AstraZeneca

NCT06989112

Recruiting Phase 3 582 target

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

AstraZeneca

NCT06350097

Recruiting Phase 3 572 target

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

AstraZeneca

NCT06346392

Recruiting 550 target

ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)

University of Michigan

NCT05388708

Recruiting NA 525 target

Multisite Advancement of Research on Chronic Posttraumatic Headache

The University of Texas Health Science Center at San Antonio

NCT05620719

Recruiting Phase 2 500 target

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Giselle Sholler

NCT02559778

Recruiting 500 target

Clinical Data Registry of Amblyopia Patients on Luminopia Treatment

Luminopia

NCT06429280

Recruiting Phase 3 487 target

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Eli Lilly and Company

NCT06948435

Recruiting Phase 3 487 target

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

Eli Lilly and Company

NCT06952530

Recruiting Phase 3 480 target

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

Dianthus Therapeutics

NCT06858579

Recruiting Phase 2 474 target

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Alliance for Clinical Trials in Oncology

NCT06632977

Recruiting Phase 3 444 target

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Amgen

NCT06700343

Recruiting Phase 2 441 target

Neuroblastoma Maintenance Therapy Trial

Giselle Sholler

NCT02679144

Recruiting 420 target

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Children's Oncology Group

NCT01790152

Recruiting Phase 2 407 target

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

Novartis Pharmaceuticals

NCT07094516

Recruiting Phase 3 400 target

Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment

University of Rochester NCORP Research Base

NCT04829539

Recruiting Phase 3 348 target

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

National Cancer Institute (NCI)

NCT04530565

Recruiting Phase 2 335 target

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

National Cancer Institute (NCI)

NCT05554406

Recruiting 330 target

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

Children's Oncology Group

NCT05702645

Recruiting Phase 3 324 target

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

AstraZeneca

NCT05261399

Recruiting Phase 1 289 target

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

NCT06465199

Recruiting NA 260 target

The Healthy Diet and Lifestyle Study II

University of Hawaii

NCT05132686

Recruiting NA 222 target

Symptom-Targeted Approach to Rehabilitation for Concussion (STAR-C)

Henry M. Jackson Foundation for the Advancement of Military Medicine

NCT06855186

Recruiting Phase 3 220 target

InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS

ONY

NCT05960929

Recruiting Phase 1 210 target

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Daiichi Sankyo

NCT06244485

Recruiting NA 210 target

PILI 'Āina Household

University of Hawaii

NCT06526273

Recruiting Phase 2 200 target

Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine

Global Coalition for Adaptive Research

NCT05948553

Recruiting Phase 2 200 target

Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant

Global Coalition for Adaptive Research

NCT05948540

Recruiting NA 192 target

Natives Engaged in Alzheimers Research - 'Ike Kupuna

University of Hawaii

NCT05534607

Recruiting NA 180 target

Emovi 3D Knee Assessment Device Intervention for Operational Readiness

Womack Army Medical Center

NCT06517056

Recruiting NA 180 target

Transcutaneous Electrical Nerve Stimulation for Post-Cesarean Pain Control

Hawaii Pacific Health

NCT04399707

Recruiting NA 180 target

Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device

Microvention-Terumo

NCT04839705

Recruiting Phase 2 180 target

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

ACADIA Pharmaceuticals

NCT07029581

Recruiting Phase 2 178 target

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

Boehringer Ingelheim

NCT06321302

Recruiting Phase 2 165 target

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

National Cancer Institute (NCI)

NCT05554328

Recruiting Phase 3 160 target

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Xenon Pharmaceuticals

NCT05667142

Recruiting NA 159 target

The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)

Avantec Vascular

NCT06321575

Recruiting Phase 2 150 target

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

AbbVie

NCT06568939

Recruiting Phase 2 150 target

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

National Cancer Institute (NCI)

NCT05136196

Recruiting Phase 3 146 target

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

Novartis Pharmaceuticals

NCT06517758

Recruiting NA 142 target

The Lilac Device Trial

Luminate Medical

NCT07142304

Recruiting NA 136 target

Mobile Intervention for Simultaneous Alcohol and Marijuana Use in Young Adults

Kaiser Permanente

NCT05991882

Recruiting NA 120 target

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

M.D. Anderson Cancer Center

NCT02945579

Recruiting Phase 2 118 target

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Giselle Sholler

NCT04696029

Recruiting Phase 1 104 target

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Milton S. Hershey Medical Center

NCT06541262

Recruiting NA 100 target

Rehabilitation With Empowered STrategies to Optimize REcovery

Vanderbilt University Medical Center

NCT07406997

Recruiting Phase 2 100 target

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

Reunion Neuroscience

NCT07002034

Recruiting Phase 2 98 target

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

Giselle Sholler

NCT06540963

Recruiting Phase 3 98 target

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

PedAL BCU

NCT05183035

Recruiting NA 97 target

Education & Mentorship of Advanced Practice Providers to Increase Community-based Research Within the NCORP Network, COACH-APP Trial

Wake Forest University Health Sciences

NCT06904391

Recruiting Phase 2 93 target

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Giselle Sholler

NCT05489887

Recruiting Phase 2 89 target

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

NCT07015983

Recruiting Phase 2 80 target

Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma

Queen's Medical Center

NCT04965454

Recruiting NA 76 target

Function After Anterior Cervical Discectomy and Fusion Surgery: Timing of Physical Therapy

Vanderbilt University Medical Center

NCT06202443

Recruiting NA 75 target

Quit-Smoking Study for Native Hawaiians

University of Hawaii

NCT07075575

Recruiting NA 75 target

Assessing Acceptability and Feasibiity of STI Self-swab Testing, to be Offered at the Time of Telemed Medication Abortion Provision

Queen's Medical Center

NCT06951438

Recruiting NA 74 target

Weight Loss and Physical Fitness Following Pregnancy in Active Duty Women

Tripler Army Medical Center

NCT05518604

Recruiting NA 70 target

Vapocoolant Spray to Reduce Pain With Nexplanon Insertion

Queen's Medical Center

NCT06933381

Recruiting Phase 1 70 target

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

OncoTherapy Science

NCT02926690

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Recruiting status is reported by each study's sponsor and mirrored from the public registry. Always confirm current eligibility and status on ClinicalTrials.gov before contacting a study.

Verify with NIH →